WallStSmart

Bolt Biotherapeutics (BOLT)vsEli Lilly and Company (LLY)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 1839517% more annual revenue ($86.46B vs $4.70M). LLY leads profitability with a 31.9% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 74/100 (B).

BOLT

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 5.0
Piotroski: 5/9Altman Z: -12.19

LLY

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BOLT1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.27T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
68.5%10/10

Every $100 of equity generates 68 in profit

Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
51.2%10/10

Strong operational efficiency at 51.2%

Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

Free Cash FlowQuality
$8.22B8/10

Generating 8.2B in free cash flow

Areas to Watch

BOLT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.33M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

LLY3 concerns · Avg: 2.3/10
Debt/EquityHealth
1.233/10

Elevated debt levels

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
31.7x2/10

Trading at 31.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : BOLT

The strongest argument for BOLT centers on Price/Book.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.

Bear Case : BOLT

The primary concerns for BOLT are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 1.71 is elevated, increasing financial risk.

Bear Case : LLY

The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.

Key Dynamics to Monitor

BOLT profiles as a value stock while LLY is a growth play — different risk/reward profiles.

BOLT carries more volatility with a beta of 1.01 — expect wider price swings.

LLY is growing revenue faster at 38.6% — sustainability is the question.

LLY generates stronger free cash flow (8.2B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (74/100 vs 29/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bolt Biotherapeutics

HEALTHCARE · BIOTECHNOLOGY · USA

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?